Test Code: 4178

FRAXE Syndrome: MALE CCG Repeats and Methylation
Test Code: 4178
Turnaround time: 3 weeks


In patients who have the cytogenetic changes of fragile X syndrome but lack the molecular changes characteristic of that disorder (i.e., are
FMR1-mutation negative), a second site of fragility, symbolized FRAXE, has been demonstrated to be expanded. Data suggests that an etiologic relationship may exist between FRAXE and nonspecific X-linked intellectual disability. Loss of expression of the gene AFF2 has been correlated with FRAXE expansion. Sequence analysis and deletion/duplication analysis are available to identify mutations in the AFF2 gene.

For patients with suspected FRAXE syndrome, repeat expansion testing and methylation analysis are recommended as the first step in mutation identification. For patients in whom mutations are not identified, full gene sequencing and deletion/duplication analysis are also available.


This test is indicated for:

  • Confirmation of a clinical diagnosis of FRAXE syndrome
  • Carrier testing in adult females with a family history of FRAXE syndrome


Alleles in the normal and premutation range are detected by PCR amplification and fragment analysis. Males: Methylation sensitive PCR is performed to determine AFF2 methylation status.


All cases of FRAXE syndrome caused by CCG expansion of the AFF2 gene will be detected by this assay. Rare cases of FRAXE syndrome caused by mutation of the AFF2 gene will not be detected by this assay.

Normal: Approximately 6-35 CCG repeats. Affected: Approximately >200 CCG repeats and methylation of expanded allele.


Type: Whole Blood
Specimen Requirements:
In EDTA (purple top) or ACD (yellow top) tube: Infants (2 years): 3-5 ml
Older Children & Adults: 5-10 ml

Specimen Collection and Shipping: Refrigerate until time of shipment. Ship sample within 5 days of collection at room temperature with overnight delivery.


  • Full gene sequencing and deletion/duplication analysis of the AFF2 gene are available for those individuals in whom repeat analysis and methylation testing is negative.
  • Testing for fragile X syndrome at the FRAXA site is available by repeat expansion/methylation analysis, FMR1 sequencing, and FMR1
    deletion/duplication analysis.
  • X-linked Intellectual Disability NGS Panel